CorMedix Inc. is an emerging commercial-stage biopharmaceutical company that initiated a Phase III clinical study of a novel anti-infective solution, Neutrolin in hemodialysis patients in the United States in December 2015. The Company seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of infectious and inflammatory diseases. CorMedix's first commercial product in Europe is Neutrolin®, a catheter lock solution for the prevention of catheter related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, central venous catheters used for vascular access in hemodialysis patients, in addition to oncology patients, critical care patients, and patients receiving total parenteral nutrition, IV hydration, and/or IV medications. The FDA has granted Fast Track status to Neutrolin Catheter Lock Solution and also had designated Neutrolin as a Qualified Infectious Disease Product for oncology, hemodialysis, and critical care/intensive care patients, where catheter-related blood stream infections and clotting can be life-threatening. The initial and planned indications aim to address significant needs in catheter-based treatments in the U.S. and the rest of the world.

Bedminster Township, US
Size (employees)
9 (est)
CorMedix was founded in 2006 and is headquartered in Bedminster Township, US

CorMedix Office Locations

CorMedix has an office in Bedminster Township
Bedminster Township, US (HQ)
200 1430 US-206

CorMedix Financials and Metrics

CorMedix Financials

CorMedix's revenue was reported to be $224.1 k in FY, 2016

Revenue (Q2, 2017)

136.2 k

Gross profit (Q2, 2017)

118.1 k

Gross profit margin (Q2, 2017), %


Net income (Q2, 2017)

(5.1 m)

EBIT (Q2, 2017)

(7 m)

Market capitalization (13-Nov-2017)

30.7 m

Cash (30-Jun-2017)

7.9 m
CorMedix's current market capitalization is $30.7 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016


2 k189.3 k210.1 k224.1 k

Revenue growth, %


Cost of goods sold

201.6 k445.8 k318.7 k366.7 k

Gross profit

(199.6 k)(256.5 k)(108.6 k)(142.6 k)
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


12.2 k39.7 k52.4 k31.3 k120 k35.9 k41.4 k16.5 k44.5 k39.6 k136.2 k

Cost of goods sold

81 k54.5 k36.7 k17.3 k101.8 k35.4 k50.2 k187.2 k43.9 k93.6 k18.1 k

Gross profit

(68.8 k)(14.8 k)15.8 k13.9 k18.2 k551(8.8 k)(170.7 k)529(54 k)118.1 k

Gross profit Margin, %

USDFY, 2013FY, 2014FY, 2015FY, 2016


2.4 m4.3 m11.8 m8.1 m


80 k166.7 k

Current Assets

2.9 m5 m37.1 m21.8 m


36.1 k41.5 k37.9 k69.7 k
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


483.1 k9.2 m7.7 m5.9 m8.8 m24.1 m14.2 m13.2 m12 m9.8 m6.8 m7.9 m


270.5 k63.7 k278 k677.4 k461.4 k715 k699.1 k333.9 k157.5 k118.2 k94.9 k313.1 k

Current Assets

1 m9.7 m8.2 m6.8 m9.7 m38.7 m39.3 m33.6 m31.2 m28.8 m14.9 m21.1 m


3 k33.6 k54.2 k46.9 k47 k44.7 k41.1 k34.8 k31.9 k75.8 k63.2 k57 k
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(9.1 m)(20.5 m)(18.2 m)(24.6 m)


80 k

Accounts Payable

939.8 k893.4 k1.7 m1.6 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(2.5 m)(16.7 m)3.5 m(5 m)(5.5 m)(4.1 m)(4.7 m)(4.2 m)(4.9 m)(9.1 m)(7.6 m)


278 k677.4 k

Accounts Payable

848.6 k740.3 k1.4 m1.1 m1.4 m1.6 m1.1 m1.8 m1.7 m
Y, 2017

Financial Leverage

1.4 x
Show all financial metrics

CorMedix Market Value History

CorMedix's Web-traffic and Trends

CorMedix Online and Social Media Presence

CorMedix Company Life and Culture

You may also be interested in